Jerusalem, Israel

Oramed Pharmaceuticals

oramed.com
Jerusalem, Israel
SEARCH FILTERS
Time filter
Source Type

News Article | May 18, 2017
Site: www.prnewswire.com

JERUSALEM, May 18, 2017 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that  Chief Executive Officer, Nadav Kidron, will present at three conferen...


News Article | July 18, 2017
Site: www.prnewswire.com

JERUSALEM, July 18, 2017 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (www.oramed.com), a developer of oral drug delivery systems, announced today the appointment of Dr. Simon Bruce MD to the newly created position of Vice President of Medical Affairs. "We are very...


News Article | July 12, 2017
Site: www.prnewswire.com

JERUSALEM, July 12, 2017 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that Dr. Miriam Kidron, Oramed's Chief Scientific Officer, will deliver a...


News Article | June 27, 2017
Site: www.prnewswire.com

JERUSALEM, June 27, 2017 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the Japanese Intellectual Property Office has publicized its intent...


News Article | May 9, 2017
Site: www.prnewswire.com

JERUSALEM, May 9, 2017 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the Canadian Intellectual Property Office has granted Oramed a patent...


News Article | June 6, 2017
Site: www.prnewswire.com

JERUSALEM, June 6, 2017 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (http://www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that a scientific abstract summarizing the recent Phase IIb study of...


News Article | September 25, 2017
Site: www.prnewswire.com

JERUSALEM, Sept. 25, 2017 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ/TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the Company will participate in the upcoming 2017 Disruptive...


— Market Scenario: Human insulin is also known as synthetic insulin which is prepared in laboratory and has same characteristics like natural insulin. Human insulin was developed through the 1960s and 1970s and approved for pharmaceutical use in 1982. Before the invention of human insulin animal insulin, usually a purified form of porcine was used. The market for global human insulin is expected to reach up to $40 billion by the end of the forecasted period and is expected to grow at a CAGR of ~10-12%. The major factors contributing to the market growth are; increase in prevalence of diabetic population, rise in geriatric population, rising awareness of diabetes and rising prevalence of obesity. “Ask for your specific company profile and country level customization on reports” Key Players Adocia (France.) Merck & Co. (U.S.) Julphar (UAE) Bristol-Myers Squibb Company (U.S.) GlaxoSmithKline Plc (U.K.) Biocon Ltd. (India) Tonghua Dongbao Pharmaceuticals Co., Ltd. (China) Oramed Pharmaceuticals, Inc. (Israel) Novo Nordisk A/S (Denmark) However, strict regulatory requirements for approval of insulin and high cost of analog are inhibiting the growth of the global human insulin market. Along with that, delayed onset of action, and various side effects of human insulin are also limiting the growth of this market across the globe. Key Findings • Increasing prevalence of diabetic population, rising prevalence of obesity, and rise in geriatric population are major factors driving the growth of the human insulin market • Strict regulatory requirements for approval of insulin and high cost of insulin analog inhibits the growth of the Human Insulin Market • Geographically, North America has the largest share in global human insulin market, while Asia-Pacific has emerged as the fastest growing region • Based on the type, modern human insulin has the largest market share in the human insulin market Taste the market data and market information presented through more than 85 market data tables and figures spread in 180 numbers of pages of the project report. Avail the in-depth table of content TOC & market synopsis on “Global human insulin Market Information- Global Forecast to 2021" Regional Analysis of Human Insulin Market Globally North America is the largest market for human insulin, large share of this market is attributed to growing prevalence of diabetes and obesity. The North American market for human insulin is expected to grow at a CAGR of XX% and is expected to reach at US$ XXX Million by the end of the forecasted period. Europe is the second-largest market for human insulin, which is expected to grow at a CAGR of XX% Table of Content 1. Report Prologue 2. Introduction 2.1 Definition 2.2 Scope of the Study 2.2.1 Research Objective 2.2.2 Assumptions 2.2.3 Limitations 2.3 Market Structure 2.4. Market Segmentation 3. Research Methodology 3.1 Research Process 3.2 Primary Research 3.3 Secondary Research 3.4 Market Size Estimation 3.5 Forecast Model 4. Market Dynamics 4.1 Drivers 4.2 Restraints 4.3 Opportunities 4.4 Mega Trends 4.5 Macroeconomic Indicators 4.6 Important Pointers By Industry Experts 4.6.1 Fastest Growing Market 4.6.2 Growth Prospects 4.7 Regulations/Acts 5. Market Factor Analysis 5.1 Value Chain Analysis 5.2 Porters 6. Human Insulin Market 2016-2020: By Types (Us $ Million) 6.1 Introduction 6.2 Historic Market Growth 6.3 Market Size (Sub Segments) 6.3.1 Traditional Human Insulin 6.3.1.1 Short Acting Human Insulin 6.3.1.2 Intermediate Acting Human Insulin 6.3.2 Modern Human Insulin 6.3.2.1 Long Acting Human Insulin 6.3.2.2 Rapid Acting Human Insulin 6.3.2.3 Premixed Human Insulin 7. Human Insulin Market, By Region Market Value & Volume Forecast (Us $ Million) 7.1 Introduction 7.2 Market Size by Region 7.2.1 Americas 7.2.1.1 North America 7.2.1.1.1 US 7.2.1.1.2 Canada 7.2.1.2 Latin America 7.2.2 Europe 7.2.2.1 Western Europe 7.2.2.1.1 Germany 7.2.2.1.2 France 7.2.2.1.2 Italy 7.2.2.1.4 Spain 7.2.2.1.5 UK 7.2.2.1.6 Rest Of Western Europe 7.2.3.1 Eastern Europe 7.2.3 Asia-Pacific 7.2.3.1 China 7.2.3.2 India 7.2.3.3 Japan 7.2.3.4 Rest of Asia Pacific 7.2.4 Middle East & Africa 8. Company Landscape 8.1 Introduction 8.2 Product Launch/Development 8.3 Partnerships and Collaborations 8.4 Acquisitions 8.5 Business Expansion Continue………….. Get List of Tables & Figures with Sample Report @ https://www.marketresearchfuture.com/sample-request/global-human-insulin-market-information-from-2011-to-2021 Modern human insulin, also known as analog insulin, is prescribed by physicians for the treatment of diabetes. It is the customized form of traditional human insulin and provides effective results in comparison to traditional human insulin. This research report has provides the insights, on various levels of analyses such industry analysis, market share analysis leading market players and their profiles. This report also helps in studying the target segments by providing views on emerging & high-growth segments and market conclusion. Together the market data comprise and discuss with the basic assessments on the competitive scenarios & strategies, of the global human insulin market, including the high-growth regions, countries and their political, economic and technological environments. Furthermore the project report also provides the views over the historical market values as well as, pricing and cost analysis of the same. Related Report Global Astigmatism Market Information, by type (Myopic Astigmatism, Hyperopic Astigmatism and others), by treatment (Corrective Lenses, Orthokeratology (Ortho-K), Surgeries and others), by end user (Hospital, Clinics and others) - Forecast to 2022 https://www.marketresearchfuture.com/reports/astigmatism-market-research-report-global-forecast-to-2022 About Market Research Future: At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services. For more information, please visit https://www.marketresearchfuture.com/sample-request/global-human-insulin-market-information-from-2011-to-2021


Patent
Oramed Pharmaceuticals | Date: 2016-01-15

This invention provides compositions comprising a protein and an omega-3 fatty acid, method for treating diabetes mellitus, comprising administering same, and methods for oral administration of a protein with an enzymatic activity, comprising orally administering same.


Patent
Oramed Pharmaceuticals | Date: 2014-04-23

This invention provides compositions comprising a protein and an omega-3 fatty acid, method for treating diabetes mellitus, comprising administering same, and methods for oral administration of a protein with an enzymatic activity, comprising orally administering same.

Loading Oramed Pharmaceuticals collaborators
Loading Oramed Pharmaceuticals collaborators